Current reports March 2, 2021<\/p>\n\n\n\n
Article 17 section 1 of the Market Abuse Regulation (MAR) \u2013 confidential information. Time: 6:30 PM<\/p>\n\n\n\n
Saudi Arabia, United Arab Emirates, Kuwait, Qatar, Bahrain, Oman, Libya, Algeria, Morocco, Iraq, South Africa, Mexico, Peru, Ecuador, Argentina, Canary Islands, Philippines, Malaysia, Thailand, Singapore and Hong Kong.<\/p>\n\n\n\n
The Management Board of Celon Pharma S.A. (the \u201cCompany\u201d) hereby informs that on March 2, 2021, it signed a licence agreement with Glenmark Pharmaceuticals Ltd with its registered seat in India (\u201cGlenmark\u201d) to cooperate in the registration, sale and distribution of a product that constitutes a combination of fluticasone and salmeterol in a dry powder inhaler (sold in Poland under the name Salmex) on the following markets:<\/p>\n\n\n\n
The agreement was concluded for a period of 10 years from the date of sales commencement in the respective markets, with the possibility of extension. The agreement gives Glenmark the exclusive right to sell the product in the above markets and the Company only the right to manufacture the product for sale in the above markets.<\/p>\n\n\n\n
The Company informed about the cooperation with Glenmark Pharmaceuticals Europe Ltd. with its registered seat in the UK regarding the licensing agreement, with respect to 15 European countries, for the aforementioned product in the prospectus approved by the Polish Financial Supervision Authority on August 29, 2016.<\/p>\n","protected":false},"excerpt":{"rendered":"